Krystal Biotech (KRYS) Corporate presentation summary

Financial performance and growth

• Achieved over $846M in net revenue from VYJUVEK since launch, with 11 consecutive quarters of positive EPS.

• Cash and investments totaled $1.017B as of 1Q 2026, supporting ongoing R&D and expansion.

• Strong U.S. launch of VYJUVEK, with over 695 patients receiving reimbursement approvals and broad coverage across all ages and genetic subtypes.

• Global expansion underway, with launches in France, Germany, and Japan in 2H 2025 and over 1.3K identified DEB patients in these markets.

• Two U.S. CGMP manufacturing facilities totaling over 175K sq ft ensure robust in-house production capacity.

Product pipeline and innovation

• VYJUVEK is the first corrective therapy for dystrophic epidermolysis bullosa (DEB), addressing a high unmet need and now approved for all ages and wound types.

• Deep pipeline leveraging a redosable HSV-1 platform, with programs in cystic fibrosis (KB407), AATD lung disease (KB408), ophthalmology (KB803, KB801), dermatology (KB111), oncology (KB707), and aesthetics (JEUNE/KB304).

• Platform technology designation granted by FDA for three pipeline programs, accelerating development and de-risking regulatory pathways.

• Multiple late-stage clinical trials ongoing, including registrational studies in ophthalmology and respiratory indications.

• A wholly owned aesthetics subsidiary, JEUNE, is advancing programs targeting skin rejuvenation and anti-aging.

Clinical and regulatory milestones

• VYJUVEK pivotal study showed significant wound closure rates and strong safety profile, with no treatment discontinuations or deaths.

• KB803 and KB801 in registrational studies for DEB ocular complications and neurotrophic keratitis, with top-line data expected in 2026.

• KB407 and KB408 demonstrated successful gene delivery and protein expression in Phase 1 studies for cystic fibrosis and AATD, with repeat dosing data expected later this year.

• Oncology candidate KB707 showed a 36% objective response rate in advanced NSCLC patients, with RMAT designation granted and combination data expected in 2026.

• Dermatology candidate KB111 for Hailey-Hailey disease granted Fast Track and platform technology designations, with clinical data updates expected in 2026.